-
TJ Biopharma and Jumpcan Pharmaceutical Announce NMPA Review of Eftansomatropin Alfa BLA
•
Chinese partners TJ Biopharma and Jumpcan Pharmaceutical (SHA: 600566) have jointly announced that the National Medical Products Administration (NMPA) of China has accepted a Biologic License Application (BLA) for eftansomatropin alfa (TJ101) for review. This product, the first and currently only fusion protein long-acting growth hormone, is anticipated to offer…
-
TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China
•
TJ Biopharma, a biopharmaceutical company based in China, has entered into a licensing agreement with the French pharmaceutical giant Sanofi. This agreement grants Sanofi exclusive rights to develop, manufacture, and commercialize TJ Biopharma’s anti-CD73 antibody, uliledlimab (TJD5), in Greater China. As part of the deal, Sanofi will make an upfront…
